250 related articles for article (PubMed ID: 28461240)
1. Safety pharmacology methods and models in an evolving regulatory environment.
Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
[TBL] [Abstract][Full Text] [Related]
2. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
[TBL] [Abstract][Full Text] [Related]
3. Safety pharmacology 2023 and implementation of the ICH E14/S7B Q&A guidance document.
Pugsley MK; Koshman YE; Foley CM; Winters BR; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2023; 123():107300. PubMed ID: 37524151
[TBL] [Abstract][Full Text] [Related]
4. The shifting landscape of safety pharmacology in 2015.
Pugsley MK; Authier S; Stonerook M; Curtis MJ
J Pharmacol Toxicol Methods; 2015; 75():5-9. PubMed ID: 26055120
[TBL] [Abstract][Full Text] [Related]
5. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
6. Safety pharmacology in 2014: new focus on non-cardiac methods and models.
Pugsley MK; Dalton JA; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2014; 70(2):170-4. PubMed ID: 25128820
[TBL] [Abstract][Full Text] [Related]
7. Innovation in safety pharmacology testing.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
[TBL] [Abstract][Full Text] [Related]
8. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
9. An overview of the safety pharmacology society strategic plan.
Pugsley MK; Authier S; Koerner JE; Redfern WS; Markgraf CG; Brabham T; Correll K; Soloviev MV; Botchway A; Engwall M; Traebert M; Valentin JP; Mow TJ; Greiter-Wilke A; Leishman DJ; Vargas HM
J Pharmacol Toxicol Methods; 2018; 93():35-45. PubMed ID: 29330132
[TBL] [Abstract][Full Text] [Related]
10. Reprint of "Safety pharmacology in 2014: New focus on non-cardiac methods and models".
Pugsley MK; Dalton JA; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2014; 70(3):199-203. PubMed ID: 25467811
[TBL] [Abstract][Full Text] [Related]
11. Safety pharmacology methods and regulatory considerations evolve together.
Pugsley MK; Harter ML; de Korte T; Connaughton C; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2018; 93():1-6. PubMed ID: 29936032
[No Abstract] [Full Text] [Related]
12. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
13. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.
Abi-Gerges N; McMahon C; Vargas H; Sager P; Chui R; Stevens D; Davila J; Schaub JR; Wu JC; Del Rio C; Mathes C; Miller PE; Burns-Naas LA; Ghetti A
J Pharmacol Toxicol Methods; 2019; 98():106582. PubMed ID: 31077805
[TBL] [Abstract][Full Text] [Related]
14. Innovative approaches to cardiovascular safety pharmacology assessment.
Pugsley MK; Winters BR; Koshman YE; Authier S; Foley CM; Hayes ES; Curtis MJ
J Pharmacol Toxicol Methods; 2024 Jun; ():107533. PubMed ID: 38945308
[TBL] [Abstract][Full Text] [Related]
15. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
16. The northeast regional SPS meeting update: Safety pharmacology innovations and applications.
Pannirselvam M; Brabham T; Botchway AW; Hodges DB; Traebert M; Pugsley MK
J Pharmacol Toxicol Methods; 2017; 85():82-86. PubMed ID: 27913272
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
[TBL] [Abstract][Full Text] [Related]
18. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
19. 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.
Cavero I
Expert Opin Drug Saf; 2014 Sep; 13(9):1271-81. PubMed ID: 25054438
[TBL] [Abstract][Full Text] [Related]
20. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
